Gilead Beats $50M Drug Bonus Call In Del. Chancery Ruling
Gilead Sciences Inc. defeated a merger partner's $50 million cancer-drug bonus demand after a Delaware Chancery Court ruled Wednesday that the Calistoga Pharmaceuticals Inc. compound involved never won the broad approval...To view the full article, register now.
Already a subscriber? Click here to view full article